Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Clinical trial NCT05043688 · RECRUITING

Trial details

NCT number: NCT05043688
Sponsor: Zhigang Li
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Resectable Esophageal Squamous Cell Carcinoma

Start date: 2021-09-01
Primary completion: 2028-12-31
Enrollment: 426

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.